Mission

To develop good practices for outcomes research in the study design and utilization of genomics involved in personalized/precision medicine.

Background

The term "personalized medicine" is often described as providing "the right patient with the right drug at the right dose at the right time. More broadly, personalized medicine (also known as precision medicine) may be thought of as the tailoring of a medical treatment to the individual’s characteristics, needs, and preferences during all stages of care, including prevention, diagnosis, treatment, and follow-up.

Leadership:

Emily Reese, PhD MPH

Director, Translational Research, Levine Cancer Institute
NC, United States

Molly Purser, MBA BS PhD

Chair
Associate Director, Health Economics, RTI-Health Solutions
NC, United States

Working Groups:


Key Project

Real-world evidence to address uncertainty for transformative and curative therapies

Co-chairs:

  • Eric Faulkner, MPH, Vice President, Real World Value and Strategy, Executive Director, Precision and Transformative Medicine Center of Excellence, Evidera
  • Sue Zelt, DrPH, Principal and consultant, Cere Health Research
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×